Corewell

Patient Name DOB MRN Physician

CSN

Physician's Orders ALÉMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) -ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER Page 1 of 3

age . c	. •								
Anticipated I	nfusion Da	ate	_ ICD 10 Code with [Description					
Height		(cm) Weight	(kg) Allergie	es					
Provider Sp	ecialty								
□ Allergy/Im	munology	☐ Infectious Dis	ease	□ OB/GYN	☐ Rheumatology				
☐ Cardiology		☐ Internal Med/Family Practice		☐ Other	☐ Surgery				
☐ Gastroenterology		☐ Nephrology		□ Otolaryngology	☐ Urology				
☐ Genetics		☐ Neurology		☐ Pulmonary	☐ Wound Care				
Site of Serv									
□ CH Blodgett (GR)		☐ CH Helen DeVos (GR)		☐ CH Ludington	☐ CH Reed City				
☐ CH Gerber		☐ CH Lemmen Holton (GR)		□ CH Pennock	☐ CH Zeeland				
☐ CH Green									
Treatment in									
☐ Conditioning		☐ Curative		☐ Mobilization	☐ Supportive				
☐ Control		□Maintenance		☐ Palliative					
Types:	NON ON	COLOGY SUPPO	DTIVE CADE						
				RANSPLANT, CLAD, BOS	SILING				
				Cycle length:					
Day 1	Alomaz	unido 10	ocat i amo	Oyolo longui.	Perform every 1 day x 1				
	Appointme	nt Requests							
			ULATED LENGTH IN	IFUSION					
	· ·	APPOINTMENT Expected: S. Ex		REQUEST 1 ires: S+365, 90 minutes (calculated), Schedule appointment at most 3 days					
		before or 3 days after							
	Vitals								
_		VITAL SIGNS	S						
		Interval: EVERY 15 MIN							
		0	\/''\						
		Comments:		Vital signs (HR, BP, RR, temp, and pulse ox) prior to alemtuzumab then every 15 min x 2 and every 30 minutes x 3 after then routine.					
			every 15 min x 2 c	and every 50 minutes x c	diter their routine.				
	Nursing Or	ders							
ONC NURSING COMMUNICATION 33 Interval: Until discontinued									
		Comments:	ALEMTUZUMAB:						
			Check vital signs and pulse oximetry before dose then q 15 min X 2 and q 30 min X 3 after alemtuzumab						
			4 00 min X 0 alter alemtuzuman						
			Assess for signs and symptoms of anaphylaxis q 15 min X 2 and q 30 min X 3 after alemtuzumab						
			Notify transplant physician or advance practice provider if the following occur: respiratory compromise (dyspnea, wheezing, bronchospasm, drop in oxygen saturation), systolic blood pressure less than 90 mm Hg, heart rate less than 60 bpm or greater than 120 bpm, temperature greater than 38°C/100.4°F, local skin reaction at injection site.						
			Monitor injection s	site after alemtuzumab fo	r signs of local skin reaction.				





Patient Name

DOB

MRN

Physician

CSN

ALEMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) -

ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 2 of 3

Nursing Orders

ONC NURSING COMMUNICATION 100

Interval: Until discontinued

May Initiate IV Catheter Patency Adult Protocol Comments:

Hypersensitivity Reaction Adult Oncology Protocol

Interval: Until discontinued

Comments:

Routine. Until Discontinued Starting: when released for 24 hours

HYPERSENSITIVITY REACTIONS:

Discontinue the medication infusion immediately.

Activate emergency response for severe or rapidly progressing symptoms. Where available consider calling RAP and have crash cart available. Call 911 or code team (if applicable) as needed for an absence of pulse and respirations. Refer to site specific emergency response

Stay with patient until symptoms have resolved.

Initiate/Continue Oxygen to maintain SpO2 greater than 90% and discontinue oxygen Therapy to maintain SpO2 above 90%

For severe or rapidly progressing hypersensitivity reaction symptoms, monitor vital signs and pulse oximeter readings every 2 to 5 minutes until the patient is stable and symptoms resolve.

Document medication infusing and approximate dose received at time of reaction in the patient medical record. Document allergy to medication attributed with causing reaction in patient medical record. Complete Adverse Drug Reaction form per Pharmacy Clinical Policy.

Pre-Medications

methylPREDNISolone sodium succinate (SOLU-Medrol): CHOOSE ONE

For patients NOT receiving pulse steroids: methylPREDNISolone sodium succinate

(SOLU-Medrol) injection

Dose: 60 mg Route: Intravenous Occurrence: Once over 5 Minutes for 1 dose

Offset: 0 Hours

Instructions:

Administer 30 to 60 minutes prior to alemtuzumab

Refer to IV Push policy for maximum IV Push dose and rate. Do not administer doses greater than 125 mg by IV Push.

For patients receiving pulse steroids: methylPREDNISolone sodium succinate

(SOLU-Medrol) intravenous in sodium chloride 0.9% 250 mL

Dose: 1,000 mg Occurrence: Once over 60 Minutes Route: Intravenous

(266 mL/min) for 1 dose

Offset: 0 Hours

Instructions:

Administer 60 minutes prior to alemtuzumab

Pre-Medications





Patient Name

DOB

MRN

Physician

CSN

ALEMTUZUMAB (CAMPATH) FOR CHRONIC LUNG ALLOGRAFT DYSFUNCTION (CLAD) -

ADULT, OUTPATIENT, COREWELL HEALTH INFUSION CENTER (CONTINUED) Page 3 of 3

diphenhydrAMINE (BENADRYL) capsule 50 mg

Dose: 50 mg Route: Oral Occurrence: Once for 1 dose

Offset: 0 Hours

Instructions:

Administer 30 to 60 minutes prior to alemtuzumab

Pre-Medications

acetaminophen (TYLENOL) tablet 650 mg

Dose: 650 mg

Occurrence: Once for 1 dose

Offset: 0 Hours

Instructions:

Administer 30 to 60 minutes prior to alemtuzumab

Route: Oral

Medications

(+)

alemtuzumab (CAMPATH) 30 MG/ML injection SOLN

Dose: 30 mg Route: Subcutaneous

Occurrence: Once for 1 dose

Offset: 60 Minutes

Instructions:

Do not administer by IV push or IV bolus.

Protect from light.

Supportive Care

diphenhydrAMINE (BENADRYL) injection 25 mg

Dose: 25 mg Route: Intravenous

Start: S

Occurrence: Every 4 hours PRN

For itching and/or rash

Supportive Care

ondansetron (ZOFRAN-ODT) disintegrating tab 4 mg

Dose: 4 mg Start: S

Route: Oral

Occurrence: Every 6 hours PRN

For nausea and vomiting

For administration of oral disintegrating tablets, peel back foil on blister pack to expose tablet; do NOT push the tablet through the foil backing. Use dry hands to remove the tablet from the blister unit and immediately place the entire tablet in the mouth. Tablets disintegrate rapidly in

saliva and can be swallowed with or without liquid.

ondansetron (ZOFRAN) IV 4 mg

Dose: 4 mg Route: Intravenous Start: S

Occurrence: Every 6 hours PRN

For nausea and vomiting

If patient cannot tolerate ODT, may give IV Push.

Telephone order/Verbal order documented and read-back completed. Practitioner's initials

NOTE: Unless Order is written DAW (dispense as written), medication may be supplied which is a generic equivalent by nonproprietary name.

	TRANSCRIBED:		VALIDATED:		ORDERED:			
	TIME	DATE	TIME	DATE	TIME	DATE	Pager#	
ĺ				R.N.		Physiciar	Physician	
		Sign		Sign		Print	t Sign	

